Worth reading
56In focus
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Improvement
Direction inferred from the company’s description.Scale
—
Displayed only when the document provides numerical figures.Wording
Definitive
How definitive the wording is.Announced details
Bilastine OD Tablets 20 mg “Daito”Letrozole Tablets 2.5 mg “Chemiphar”
Applicable field (uses covered by this announcement)
Treatment of allergic diseasesAromatase inhibitor
Launch date12 June 2026 (actual)
Relationship between the counterparty and the company
Daito Pharmaceutical Co.,Ltd.4577
Relationship with the Company
Sales companies for ダイト’s prescription drugs. 共創未来ファーマ株式会社 is the second sales company for Letrozole Tablets 2.5 mg “Chemiphar.”
Counterparty共創未来ファーマ株式会社NIPPON CHEMIPHAR CO.,LTD.株式会社フェルゼンファーマ
In this announcement the company addresses none of Contract Value / Offering price / Impact on Business Performance.
| Item | Details |
|---|---|
| Names of Products / Services Covered | Bilastine OD Tablets 20 mg “Daito”, Letrozole Tablets 2.5 mg “Chemiphar” |
| Counterparty | 共創未来ファーマ株式会社, NIPPON CHEMIPHAR CO.,LTD., 株式会社フェルゼンファーマ |
| Relationship with the Company | Sales companies for ダイト’s prescription drugs. 共創未来ファーマ株式会社 is the second sales company for Letrozole Tablets 2.5 mg “Chemiphar.” |
| Launch date | 12 June 2026 (actual) |
| Applicable area | Treatment of allergic diseases, Aromatase inhibitor |
Items this document does not state (13)
Counterparty overviewContract ValueOffering priceContract DateAward/certification nameAwarding / certifying bodyRegistration number and expiry dateLocationLocation scaleQuantitative EffectsUsage historyImpact on Business PerformanceSource
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.To announce the launch of new prescription drugs and the addition of a sales company. No specific reasons for the launches or impact on financial results are stated.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.